Drug Trial Radar · NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Sep 27, 2029
Study completion Sep 27, 2029
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Jun 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (CAR T-cell) and T-cell redirecting therapies (such as T-cell engager bispecific antibody \[TCE BsAb\] therapy). The primary objective is to demonstrate that true annualized rate of serious bacterial infection (SBIs) is less than (\<) 1.0. This study includes two cohorts: 1. Loading Cohort: Participants with serum immunoglobulin G (IgG) \< 500 milligrams per deciliter (mg/dL) at Screening, with or without ongoing immunoglobulin replacement therapy (IgRT) during Screening, who must have received five doses of IgPro20 during the Initial Treatment Period. 2. Maintenance-only Cohort: Participants with serum IgG greater than or equal to (≥) 500 mg/dL and ongoing IgRT at Screening, who must have received one dose of IgPro20 during the Initial Treatment Period.
Conditions
- Secondary Immune Deficiency
Interventions
IgPro20Biological
IgPro20 infusion administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Serious Bacterial Infections (SBIs) per ParticipantTime frame: Up to Month 12
Locations
60 sites in 11 countries. Site status is shown where the registry gives one.
UC Irvine
Orange, California · Not yet recruiting
CBCI, Colorado Blood Cancer Institute
Denver, Colorado · Not yet recruiting
SSAK Partners
Coral Springs, Florida · Recruiting
Mayo Clinic - Jacksonville
Jacksonville, Florida · Not yet recruiting
Indiana University Health Arnett, Inc.
Lafayette, Indiana · Not yet recruiting
Johns Hopkins Asthma & Allergy Center
Baltimore, Maryland · Not yet recruiting
American Oncology Partners, PA dba The Center for Cancer and Blood Disorders
Bethesda, Maryland · Recruiting
Hackensack Meridian Health
Hackensack, New Jersey · Not yet recruiting
Carol G Simon Cancer Center
Morristown, New Jersey · Not yet recruiting
David H. Koch Center for Cancer Care
New York, New York · Not yet recruiting
Montefiore Medical Center PRIME
The Bronx, New York · Not yet recruiting
Duke University
Durham, North Carolina · Not yet recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Not yet recruiting
Penn State Hershey Medical Center
Hershey, Pennsylvania · Not yet recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Not yet recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Not yet recruiting
UZ Gent
Ghent, Belgium · Not yet recruiting
CHU de Liège
Liège, Belgium · Not yet recruiting
Universitair ziekenhuis Antwerpen UZA
Edegem, Antwerp, Belgium · Not yet recruiting
AZ Delta
Roeselare, West-Vlaanderen, Belgium · Not yet recruiting
Horizon Health Network
Fredericton, New Brunswick, Canada · Not yet recruiting
McGill University Health Research Institute
Montreal, Quebec, Canada · Not yet recruiting
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia · Not yet recruiting
UHKT Praha
Prague, Czechia · Not yet recruiting
FH Ostrova
Ostrova, CZE, Czechia · Not yet recruiting
FH Hradec Kralove
Hradec Králové, Hradec Králové Region, Czechia · Not yet recruiting
Rigshospitalet
Copenhagen, Denmark · Terminated
Zealand University Hospital
Roskilde, Denmark · Not yet recruiting
Department of Medicine, Vejle Hospital
Vejle, South Region Denmark, Denmark · Not yet recruiting
Centre Henri Becquerel
Rouen, France · Not yet recruiting
CHU Rennes - Hopital Pontchaillou
Rennes, ILE ET Vilaine, France · Not yet recruiting
CHU de Nantes-Hotel Dieu
Nantes, Loire Atlantique, France · Not yet recruiting
CHU Angers - Hôpital Hôtel Dieu
Angers, Maine Et Loire, France · Not yet recruiting
Centre Hospitalier Départemental Les Oudairies
La Roche-sur-Yon, Vendée, France · Not yet recruiting
Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen
Giessen, Hesse, Germany · Not yet recruiting
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
Mainz, Rhineland-Palatinate, Germany · Not yet recruiting
Azienda Ospedaliero Universitaria Policlinico "Gaspare Rodolico - San Marco" (Presidio G. Rodolico)
Catania, Italy · Not yet recruiting
Azienda Ospedaliera Universitaria Careggi
Florence, Italy · Not yet recruiting
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, Italy · Not yet recruiting
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.